archive-au.com » AU » T » TRADERDEALER.COM.AU

Total: 417

Choose link from "Titles, links and description words view":

Or switch to "Titles and links view".
  • SOM | Online Stockmarket Trading Update
    the Dutch health insurers reimbursing patients diagnosed with obstructive sleep apnea for the first line treatment with an oral appliance instead of CPAP as exemplary for other countries in Europe The consideration for the first 50 of the capital of GS is one million Euro of which 250 000 Euro has been paid in cash and the balance by way of 805 664 shares in SomnoMed Limited issued at A 1 28 per share These Shares will be voluntarily escrowed for a period of 12 months The remaining 50 of GS will be acquired by SomnoMed over a period of 5 years in four equal annual portions commencing in April 2014 The price for these 12 5 tranches will be linked to the net profits generated by GS s business in the Netherlands and will be payable half in cash and half in shares in SomnoMed Limited www somnomed com http www traderdealer com au fundamentals som Tags acquisition European Expansion Healthcare Oral Appliances Sleep Disorders SOM Somnomed Posted in ASX Company News No Comments SomnoMed Launches New Teeth Grinding Treatment Wednesday January 20th 2010 SomnoMed Limited SOM the world s leading dental sleep appliance company announced today the launch of SomnoMed Brux SomBruxTM an innovative new range of products treating sleep bruxism Sleep Bruxism is a common sleep related movement disorder that is characterised by clenching or grinding of the jaws or teeth Medical studies indicate a prevalence of approximately 8 in the adult population of western societies and an equal occurrence in men and women The condition is currently treated with a wide range of products mostly individually made by dental technicians Based on company research the global market is currently in excess of 2 million units per year representing a wholesale value of around US 200 to 300 million with an annual growth tendency of 8 to 12 The new SomnoMed Brux product line will be introduced in Australia in February 2010 followed during the year by launches in all major global markets where SomnoMed is represented SomBruxTM like the leading SomnoDent device treating sleep apnea is custom made and offered in various designs It is expected that one of its unique selling points is the use of SomnoMed s SMH Bflex material which offers unrivalled patient comfort and durability SomnoMed s CEO Mr Ralf Barschow commented SomnoMed s mission is to treat sleep related disorders such as snoring apnea and bruxism Teeth clinching or grinding is one of the most frequent medical conditions occurring during sleep The impact of bruxism on teeth and jaws breathing neck and back conditions even general health is evolving but generally considered by practitioners as significant SomBruxTM is our treatment answer for this condition and satisfies a potential demand from a significant number of patients around the world It is a logical next step in our dental sleep appliance product range offering a combination of highest quality and excellent craftsmanship synonymous with all our SomnoMed products Over the next three years

    Original URL path: http://blog.traderdealer.com.au/tag/som/ (2013-02-03)
    Open archived version from archive

  • US Approval | Online Stockmarket Trading Update
    a treatment for obstructive sleep apnea patients This clears the way for Sleep Physicians to confidently prescribe oral appliance therapy in advance of patients being fitted with an oral appliance This is very exciting news for the sleep medical community Finally with SomnoMed MATRx it is possible to diagnose and predict treatment response with the SomnoDent therapy and is an important milestone of particular importance for non compliant CPAP patients Since the premarket launch in Minneapolis last year and in several international congresses in Japan Australia and Germany the number of enquiries never stopped With MATRx we are expecting the number of referrals for a SomnoDent therapy to increase significantly over time said Ralf Barschow CEO SomnoMed www somnomed com Tags Healthcare Sleep Monitor SOM Somnomed US approval Posted in ASX Trading News No Comments RSS Feed Twitter Follow Us Sign up to our free weekly e newsletter Feel inspired Start trading Recent Post Markets Cap Best January Performance for Over a Decade Weekly Market Wrap The Covered Call Collar Part 3 1 of Options Trading for All Types of Market Environments Stock Market Analysis Markets Cap Best January for Over a Decade Stock Market Analysis Traders Take Profits Stock Market Analysis Markets Reach Bull Market Territory Stock Market Analysis US Markets Ease Near All Time Highs Markets Higher As Investors Play Catch Up Weekly Market Wrap Investing in 2013 continued Part 9 Stock Trading Tips for All Types of Market Environments Stock Market Analysis Markets Higher As Investors Play Catchup Stock Market Analysis Markets Cautious Ahead Of Chinese Data Archives February 2013 January 2013 December 2012 November 2012 October 2012 September 2012 August 2012 July 2012 June 2012 May 2012 April 2012 March 2012 February 2012 January 2012 December 2011 November 2011 October 2011 September 2011 August 2011 July

    Original URL path: http://blog.traderdealer.com.au/tag/us-approval/ (2013-02-03)
    Open archived version from archive

  • Pharmaxis Finalises European Distribution Agreement | Online Stockmarket Trading Update
    customers Pharmaxis is a specialist pharmaceutical company involved in the research development and commercialization of therapeutic products for chronic respiratory disorders Its product Aridol for the assessment of asthma is launched in a number of key markets Its development pipeline of products includes Bronchitol for cystic fibrosis and bronchiectasis and PXS25 for the treatment of lung fibrosis and ASM8 and PXS4728 for asthma www pharmaxis com au Tags Bronchitol Distribution Agreement Healthcare Pharmaceuticals Pharmaxis PXS ASX Company News Viralytics Granted Chinese Blood Cancer Patent ASX Company News SomnoMed Cleared To Sell MATRx Sleep Monitor in US This entry was posted on Friday March 30th 2012 at 6 28 am and is filed under ASX Company News You can follow any responses to this entry through the RSS 2 0 feed You can leave a response or trackback from your own site Leave a Reply Click here to cancel reply Name required Mail will not be published required Website RSS Feed Twitter Follow Us Sign up to our free weekly e newsletter Feel inspired Start trading Recent Post Markets Cap Best January Performance for Over a Decade Weekly Market Wrap The Covered Call Collar Part 3 1 of Options Trading for All Types of Market Environments Stock Market Analysis Markets Cap Best January for Over a Decade Stock Market Analysis Traders Take Profits Stock Market Analysis Markets Reach Bull Market Territory Stock Market Analysis US Markets Ease Near All Time Highs Markets Higher As Investors Play Catch Up Weekly Market Wrap Investing in 2013 continued Part 9 Stock Trading Tips for All Types of Market Environments Stock Market Analysis Markets Higher As Investors Play Catchup Stock Market Analysis Markets Cautious Ahead Of Chinese Data Archives February 2013 January 2013 December 2012 November 2012 October 2012 September 2012 August 2012 July 2012

    Original URL path: http://blog.traderdealer.com.au/2012/03/30/asx-company-news-pharmaxis-finalises-european-distribution-agreement/ (2013-02-03)
    Open archived version from archive

  • Bronchitol | Online Stockmarket Trading Update
    to the European cystic fibrosis patients Arvato is an internationally networked outsourcing services provider employing 60 000 people in more than 30 countries Its integrated business processes and decentralized structure provide a high standard of flexible and efficient service for customers Pharmaxis is a specialist pharmaceutical company involved in the research development and commercialization of therapeutic products for chronic respiratory disorders Its product Aridol for the assessment of asthma is launched in a number of key markets Its development pipeline of products includes Bronchitol for cystic fibrosis and bronchiectasis and PXS25 for the treatment of lung fibrosis and ASM8 and PXS4728 for asthma www pharmaxis com au Tags Bronchitol Distribution Agreement Healthcare Pharmaceuticals Pharmaxis PXS Posted in ASX Company News No Comments RSS Feed Twitter Follow Us Sign up to our free weekly e newsletter Feel inspired Start trading Recent Post Markets Cap Best January Performance for Over a Decade Weekly Market Wrap The Covered Call Collar Part 3 1 of Options Trading for All Types of Market Environments Stock Market Analysis Markets Cap Best January for Over a Decade Stock Market Analysis Traders Take Profits Stock Market Analysis Markets Reach Bull Market Territory Stock Market Analysis US Markets Ease Near All Time Highs Markets Higher As Investors Play Catch Up Weekly Market Wrap Investing in 2013 continued Part 9 Stock Trading Tips for All Types of Market Environments Stock Market Analysis Markets Higher As Investors Play Catchup Stock Market Analysis Markets Cautious Ahead Of Chinese Data Archives February 2013 January 2013 December 2012 November 2012 October 2012 September 2012 August 2012 July 2012 June 2012 May 2012 April 2012 March 2012 February 2012 January 2012 December 2011 November 2011 October 2011 September 2011 August 2011 July 2011 June 2011 May 2011 April 2011 March 2011 February 2011 January 2011

    Original URL path: http://blog.traderdealer.com.au/tag/bronchitol/ (2013-02-03)
    Open archived version from archive

  • Distribution Agreement | Online Stockmarket Trading Update
    strategy of expanding its activities in the growing Intelligent Transport Systems ITS sector which involves the use of information and communication technology to manage traffic flows TTI s Road Lighting business will be based at Aldridge s offices in Rhodes NSW and will make use of TTI s existing expertise in the development of technology for use in traffic management and will leverage off TTI s existing customer base of State Road Authorities and contracting companies TTI operates through two divisions The Company s Traffic Products Division specialises in the design manufacture and installation of traffic signals emergency telephones and portable roadside technology along with a range of directional and regulatory traffic signs and traffic control products to road traffic authorities municipal councils and construction companies The Traffic Services Division provides equipment hire services to road traffic authorities and construction companies Rexel Group Australia is a major player in the distribution of electrical parts and installation equipment Rexel operates in all the States of Australia with 189 branches nationwide 3 warehouses a project office in each State and resources dedicated to supply a diversified range of products across Australia www trafficltd com au http www traderdealer com au fundamentals tti Tags Distribution Agreement Rexel Road lighting Traffic Technologies TTI Posted in ASX Company News No Comments ASX Company News Phosphagenics Enters Asian Distribution Agreement Wednesday August 3rd 2011 Melbourne biotechnology company Phosphagenics Limited POH has signed an agreement with a leading Asian distributor ensuring its Elixia personal care range will be available in stores across the Asia Pacific region by the fourth quarter 2011 The milestone distribution deal has been struck with the Sungate Supplies Pte Ltd which will exclusively supply AS Watson and Company stores commencing in Singapore A S Watson Co is a retail and consumer division of the Hong Kong based conglomerate Hutchison Whampoa Ltd and over the past decade has become the largest health and beauty retailer in the world with over 7 000 stores Announcing the agreement Phosphagenics CEO Dr Esra Ogru said while the Elixia ranges had recently achieved Australian sales target of 1 million the Asian region is the fastest growing skincare market in the world In 2010 skincare sales across the region generated 37 4 billion she noted We are very excited about this milestone This is in line with our strategy to become an international skincare brand We are continuing to pursue other opportunities in the Asia region as well as Europe and the US Phosphagenics is on track to meet its stated goal of becoming financially independent by the end of 2012 said Dr Ogru Elixia is an Australian owned and developed brand which includes anti ageing skincare formulas specially developed to penetrate and target fine lines and wrinkles The active anti ageing ingredients include SNAP 8 Carnosine and CoQ10 TPM is a patented world first delivery technology which enables superior penetration of these active ingredients into the skin Phosphagenics is commercialising drug delivery applications based on its novel transdermal drugs administered via skin TPM Targeted Penetration Matrix technology TPM is a patient friendly and cost effective system used to deliver proven pharmaceutical and nutraceutical products The lead product advancing through clinical trials is an oxycodone matrix system for the relief of chronic pain www phosphagenics com www elixia com au http www traderdealer com au fundamentals poh Tags Asia Cosmetics Distribution Agreement Elixia Phosphagenics POH Posted in ASX Company News No Comments ASX Company News AtCor Medical Enters Distribution Agreement With SunTech Medical Thursday July 28th 2011 AtCor Medical ACG the developer and marketer of the SphygmoCor system which measures central blood pressures and arterial stiffness noninvasively and SunTech Medical Inc a leader in noninvasive blood pressure products and technologies announced that they have entered into an exclusive multi year worldwide clinical trials distribution and data management agreement SunTech technology is especially well suited for clinical trials and features the patented OrbitTM blood pressure cuff which is specifically designed for ambulatory wear thus promoting patient comfort and compliance and improving data yield This expansion of core lab services offers pharmaceutical companies CRO s and other researchers from a single source greatly improved reliability and quality of information on the effects of drugs on central and peripheral hemodynamics critically important data in identifying drug benefits as well as potential patient risk AtCor Medical provides comprehensive trials support services technology sales and leasing trial site training data quality assurance and best in class data management using the AtCor WISDOM system The WISDOM system allows real time data quality assurance through secure instantaneous transmission of data from the clinical trials site to AtCor s data management center We are delighted to be working with SunTech said Duncan Ross AtCor Medical CEO This is an important addition to our portfolio It will further enhance our relationship with key pharmaceutical customers and build on the strong business fundamentals we have established in the clinical trials market With this new offering clinical trials customers can choose from an expansive portfolio that includes noninvasive central blood pressure assessment pulse wave velocity measurement heart rate variability testing and ambulatory blood pressure monitoring all backed by AtCor Medical s best in class support services For over twenty years SunTech Medical has been the preeminent supplier of clinical grade blood pressure monitoring products and technologies SunTech produces the leading cardiac stress test blood pressure monitor and is the world s foremost manufacturer of ambulatory blood pressure monitoring ABPM products SunTech Medical also offers solutions for in office BP monitoring as well as a complete line of blood pressure cuffs designed for general and specific applications AtCor Medical develops and markets products for the early detection of cardiovascular risk and management of cardiovascular disease Its technology allows researchers and clinicians to measure central blood pressure non invasively www atcormedical com http www traderdealer com au Fundamentals acg Tags ACG AtCor Medical Blood Pressure Monitor Distribution Agreement Suntech Medical Posted in ASX Company News ASX Trading News No Comments ASX Company

    Original URL path: http://blog.traderdealer.com.au/tag/distribution-agreement/ (2013-02-03)
    Open archived version from archive

  • Pharmaceuticals | Online Stockmarket Trading Update
    for the supply of Bronchitol across Europe In anticipation of a second quarter commercial launch of Bronchitol for cystic fibrosis in Europe Pharmaxis has signed a three year agreement with Arvato Healthcare a member of the Bertelsmann AG group of companies Pharmaxis Chief Executive Officer Dr Alan Robertson said This agreement completes the infrastructure required to make Bronchitol available throughout Europe Arvato provides Pharmaxis with a state of the art healthcare distribution facility centralised in Germany from which Bronchitol is shipped directly to pharmacies and hospitals Launch stock of Bronchitol is in the final stages of manufacture and our Pharmaxis and Quintiles sales teams are introducing Pharmaxis to cystic fibrosis centres in the United Kingdom and Germany The customer services and logistics are now also in place We are looking forward to making Bronchitol available to the European cystic fibrosis patients Arvato is an internationally networked outsourcing services provider employing 60 000 people in more than 30 countries Its integrated business processes and decentralized structure provide a high standard of flexible and efficient service for customers Pharmaxis is a specialist pharmaceutical company involved in the research development and commercialization of therapeutic products for chronic respiratory disorders Its product Aridol for the assessment of asthma is launched in a number of key markets Its development pipeline of products includes Bronchitol for cystic fibrosis and bronchiectasis and PXS25 for the treatment of lung fibrosis and ASM8 and PXS4728 for asthma www pharmaxis com au Tags Bronchitol Distribution Agreement Healthcare Pharmaceuticals Pharmaxis PXS Posted in ASX Company News No Comments ASX Company News Campbell Bros Acquires Two New Food Testing Facilities Tuesday March 20th 2012 Campbell Brothers Limited CPB announces that its testing services business the ALS Group has entered into an agreement to acquire all the issued share capital in Eclipse Scientific Group Limited Eclipse and Advanced Micro Services AMS from Environmental Scientifics Group in the United Kingdom for an Enterprise Value of approximately 39 million Australian Dollars The acquisition is to be funded from existing cash reserves and loan facilities with completion anticipated to take place on the 3rd April 2012 Greg Kilmister Campbell Brothers Managing Director commented The acquisition of Eclipse and AMS will provide ALS with the opportunity to expand our existing food and pharmaceutical services into new geographies in the UK and Ireland The food testing facilities in the UK and Ireland will allow us to accelerate the development of a global food and pharmaceutical testing business and help build our overall presence in Europe This acquisition will bring our total staff number in Europe to in excess of 1000 Campbell Brothers is a leading commercial services company operating one of the world s largest analytical and testing services businesses as well as commercial chemical solutions throughout Australia and the Pacific and hospitality wares and distribution throughout Australia Founded in 1863 and listed on the ASX in 1952 Campbell Brothers currently employs over 11 000 staff operating from 300 sites in 55 countries worldwide UK based Eclipse is a provider of food dairy water and pharmaceutical testing services to a blue chip customer base comprising manufacturers food processors and retailers AMS is an Ireland based laboratory group providing similar services and operates 2 laboratories with 65 staff Eclipse and AMS will be integrated into the newly formed Life Sciences Division of ALS and are an important part of ALS s strategy to build a global food pharmaceutical laboratory services business ALS is a world leader in testing and technical services in the geochemistry metallurgy coal environmental tribology food pharmaceutical inspection and industrial markets www campbell com au Tags acquisition Campbell Bros CPB Food testing Pharmaceuticals Posted in ASX Company News No Comments ASX Company News Pharmaxis Enters JV Agreement TO Market Bronchitol In Europe Wednesday September 1st 2010 Pharmaceutical company Pharmaxis PXS announced it has finalised a strategic marketing and sales service agreement for the commercialisation of Bronchitol for cystic fibrosis in Europe Ahead of anticipated regulatory approval for Bronchitol Pharmaxis has signed a six year agreement with the highly respected Quintiles organisation to support the launch and commercialisation of the product in Western Europe Pharmaxis Acting Chief Executive Officer Gary Phillips said This important development means that Pharmaxis will move into the key European markets with a clear commercialisation plan We will be bringing on board the European expertise and capabilities of a well recognised team of leaders in the field Bronchitol is a new advance in the treatment of cystic fibrosis and it s vital that we engage fully with the CF communities healthcare professionals funding bodies and governments across Europe as efficiently as possible We have selected Quintiles to help manage market launch and accelerate product uptake because the local experience of the Quintiles organisation will allow rapid access to each of the individual country markets Quintiles is a global biopharmaceutical services company offering clinical commercial consulting and capital solutions The Quintiles network employs 20 000 people across 60 countries Once approved Pharmaxis plans to launch Bronchitol across Western Europe initially in Germany and the UK in the first quarter of 2011 The Pharmaxis contract sales representatives will be supported and managed by the Quintiles organisation throughout Western Europe while marketing and market support will be managed by the Pharmaxis office in the UK Quintiles will provide a broad range of commercial support for Bronchitol including development of the overall market access strategy pricing and reimbursement local market access and recruitment and management of field based sales teams and product managers Pharmaxis Ltd is a specialist pharmaceutical company involved in the research development and commercialization of therapeutic products for chronic respiratory and immune disorders www pharmaxis com au http www traderdealer com au Fundamentals pxs Tags Cystic Fibrosis JV Agreement Pharmaceuticals Pharmaxis PXS Posted in ASX Company News No Comments ASX Company News HalcyGen Pharmaceuticals Enters Asian Distribution Agreement Friday August 27th 2010 HalcyGen Pharmaceuticals Limited HGN is pleased to announce that it has signed a distribution agreement with Pan Malayan Pharmaceuticals Pte Ltd for

    Original URL path: http://blog.traderdealer.com.au/tag/pharmaceuticals/ (2013-02-03)
    Open archived version from archive

  • Pharmaxis | Online Stockmarket Trading Update
    teams are introducing Pharmaxis to cystic fibrosis centres in the United Kingdom and Germany The customer services and logistics are now also in place We are looking forward to making Bronchitol available to the European cystic fibrosis patients Arvato is an internationally networked outsourcing services provider employing 60 000 people in more than 30 countries Its integrated business processes and decentralized structure provide a high standard of flexible and efficient service for customers Pharmaxis is a specialist pharmaceutical company involved in the research development and commercialization of therapeutic products for chronic respiratory disorders Its product Aridol for the assessment of asthma is launched in a number of key markets Its development pipeline of products includes Bronchitol for cystic fibrosis and bronchiectasis and PXS25 for the treatment of lung fibrosis and ASM8 and PXS4728 for asthma www pharmaxis com au Tags Bronchitol Distribution Agreement Healthcare Pharmaceuticals Pharmaxis PXS Posted in ASX Company News No Comments ASX Company News Pharmaxis Enters JV Agreement TO Market Bronchitol In Europe Wednesday September 1st 2010 Pharmaceutical company Pharmaxis PXS announced it has finalised a strategic marketing and sales service agreement for the commercialisation of Bronchitol for cystic fibrosis in Europe Ahead of anticipated regulatory approval for Bronchitol Pharmaxis has signed a six year agreement with the highly respected Quintiles organisation to support the launch and commercialisation of the product in Western Europe Pharmaxis Acting Chief Executive Officer Gary Phillips said This important development means that Pharmaxis will move into the key European markets with a clear commercialisation plan We will be bringing on board the European expertise and capabilities of a well recognised team of leaders in the field Bronchitol is a new advance in the treatment of cystic fibrosis and it s vital that we engage fully with the CF communities healthcare professionals funding bodies and governments across Europe as efficiently as possible We have selected Quintiles to help manage market launch and accelerate product uptake because the local experience of the Quintiles organisation will allow rapid access to each of the individual country markets Quintiles is a global biopharmaceutical services company offering clinical commercial consulting and capital solutions The Quintiles network employs 20 000 people across 60 countries Once approved Pharmaxis plans to launch Bronchitol across Western Europe initially in Germany and the UK in the first quarter of 2011 The Pharmaxis contract sales representatives will be supported and managed by the Quintiles organisation throughout Western Europe while marketing and market support will be managed by the Pharmaxis office in the UK Quintiles will provide a broad range of commercial support for Bronchitol including development of the overall market access strategy pricing and reimbursement local market access and recruitment and management of field based sales teams and product managers Pharmaxis Ltd is a specialist pharmaceutical company involved in the research development and commercialization of therapeutic products for chronic respiratory and immune disorders www pharmaxis com au http www traderdealer com au Fundamentals pxs Tags Cystic Fibrosis JV Agreement Pharmaceuticals Pharmaxis PXS Posted in

    Original URL path: http://blog.traderdealer.com.au/tag/pharmaxis/ (2013-02-03)
    Open archived version from archive

  • Viralytics Granted Chinese Blood Cancer Patent | Online Stockmarket Trading Update
    that occur naturally in the community CVA21 and EV1 attach to the outside of cells using a specific receptor on the cell s surface like a key fitting a lock CVA21 uses the receptors intercellular adhesion molecule 1 ICAM 1 and or decay accelerating factor DAF to bind and infect target cells Both of these receptor proteins have been demonstrated to be highly expressed on multiple cancer types including melanoma prostate cancer breast cancer multiple myeloma and others EV1 uses the receptor integrin α2β1 alpha 2 beta 1 receptorto bind and infect target cells www viralytics com Tags Biotechnology Cancer treatment Patent Granted Viralytics VLA Dividends Waterco Ex Dividend On 30 4 2012 ASX Company News Pharmaxis Finalises European Distribution Agreement This entry was posted on Friday March 30th 2012 at 6 25 am and is filed under ASX Company News You can follow any responses to this entry through the RSS 2 0 feed You can leave a response or trackback from your own site Leave a Reply Click here to cancel reply Name required Mail will not be published required Website RSS Feed Twitter Follow Us Sign up to our free weekly e newsletter Feel inspired Start trading Recent Post Markets Cap Best January Performance for Over a Decade Weekly Market Wrap The Covered Call Collar Part 3 1 of Options Trading for All Types of Market Environments Stock Market Analysis Markets Cap Best January for Over a Decade Stock Market Analysis Traders Take Profits Stock Market Analysis Markets Reach Bull Market Territory Stock Market Analysis US Markets Ease Near All Time Highs Markets Higher As Investors Play Catch Up Weekly Market Wrap Investing in 2013 continued Part 9 Stock Trading Tips for All Types of Market Environments Stock Market Analysis Markets Higher As Investors Play Catchup Stock

    Original URL path: http://blog.traderdealer.com.au/2012/03/30/asx-company-news-viralytics-granted-chinese-blood-cancer-patent/ (2013-02-03)
    Open archived version from archive



  •